David Verbel

4.1k total citations
46 papers, 2.9k citations indexed

About

David Verbel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David Verbel has authored 46 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in David Verbel's work include Prostate Cancer Treatment and Research (9 papers), HER2/EGFR in Cancer Research (5 papers) and Statistical Methods in Clinical Trials (5 papers). David Verbel is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), HER2/EGFR in Cancer Research (5 papers) and Statistical Methods in Clinical Trials (5 papers). David Verbel collaborates with scholars based in United States, United Kingdom and Japan. David Verbel's co-authors include Howard I. Scher, Carlos Cordon‐Cardo, Glenn Heller, Marija Drobnjak, Olivier Saidi, William Kevin Kelly, Michael J. Morris, Angeliki Kotsianti, Mikhail Teverovskiy and Ho-Yuen Pang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Brain.

In The Last Decade

David Verbel

43 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Verbel United States 21 1.2k 928 871 516 327 46 2.9k
Heikki Helin Finland 32 985 0.8× 879 0.9× 1.4k 1.6× 683 1.3× 211 0.6× 117 3.9k
Håvard E. Danielsen Norway 32 839 0.7× 949 1.0× 810 0.9× 613 1.2× 132 0.4× 104 3.5k
Stephen Yip Canada 30 1.0k 0.8× 757 0.8× 565 0.6× 356 0.7× 112 0.3× 150 2.8k
Toby C. Cornish United States 30 1.2k 1.0× 768 0.8× 1.4k 1.6× 247 0.5× 501 1.5× 75 3.6k
Timo Gaiser Germany 28 1.1k 0.9× 627 0.7× 1.4k 1.6× 868 1.7× 311 1.0× 134 3.7k
Muyan Cai China 30 1.7k 1.4× 547 0.6× 883 1.0× 272 0.5× 301 0.9× 121 3.3k
Clare Verrill United Kingdom 27 761 0.6× 453 0.5× 722 0.8× 728 1.4× 184 0.6× 102 2.7k
Giuliana Amaddeo France 21 1.1k 0.9× 581 0.6× 1.1k 1.2× 403 0.8× 464 1.4× 48 3.8k
Wentao Yang China 34 1.4k 1.1× 590 0.6× 1.7k 2.0× 425 0.8× 381 1.2× 173 3.8k
Bassam Abdulkarim Canada 32 1.3k 1.0× 878 0.9× 1.2k 1.3× 778 1.5× 174 0.5× 98 3.7k

Countries citing papers authored by David Verbel

Since Specialization
Citations

This map shows the geographic impact of David Verbel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Verbel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Verbel more than expected).

Fields of papers citing papers by David Verbel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Verbel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Verbel. The network helps show where David Verbel may publish in the future.

Co-authorship network of co-authors of David Verbel

This figure shows the co-authorship network connecting the top 25 collaborators of David Verbel. A scholar is included among the top collaborators of David Verbel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Verbel. David Verbel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Watanabe, Shunsuke, Yasuhiro Irino, David Verbel, et al.. (2022). Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimer s Research & Therapy. 14(1). 86–86. 19 indexed citations
3.
Gidal, Barry E., Rama Maganti, Antonio Laurenza, et al.. (2017). Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. Epilepsy Research. 134. 41–48. 23 indexed citations
4.
Dubbelman, Anne-Charlotte, Hilde Rosing, Cynthia M. Nijenhuis, et al.. (2014). Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 33(1). 233–240. 49 indexed citations
5.
Donovan, Michael, Angeliki Kotsianti, David Verbel, et al.. (2009). A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. European Journal of Cancer. 45(8). 1518–1526. 10 indexed citations
6.
Eggener, Scott E., Andrew J. Vickers, Angel M. Serio, et al.. (2008). Comparison of models to predict clinical failure after radical prostatectomy. Cancer. 115(2). 303–310. 13 indexed citations
7.
8.
Tabesh, Ali, Mikhail Teverovskiy, Ho-Yuen Pang, et al.. (2007). Multifeature Prostate Cancer Diagnosis and Gleason Grading of Histological Images. IEEE Transactions on Medical Imaging. 26(10). 1366–1378. 283 indexed citations
9.
Morris, Michael J., Timothy Akhurst, Steven M. Larson, et al.. (2005). Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy. Clinical Cancer Research. 11(9). 3210–3216. 86 indexed citations
10.
11.
Cordon‐Cardo, Carlos, Angeliki Kotsianti, Michael J. Donovan, et al.. (2005). 409: A Systems Pathology Approach to Predict Survival after Radical Prostatectomy. The Journal of Urology. 173(4S). 112–112. 1 indexed citations
12.
Gurrieri, Carmela, Paola Capodieci, Rosa Bernardi, et al.. (2004). Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins. JNCI Journal of the National Cancer Institute. 96(4). 269–279. 272 indexed citations
13.
Verbel, David, William Kevin Kelly, Òren Smaletz, et al.. (2003). Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. Urology. 61(1). 142–144. 6 indexed citations
14.
Slovin, Susan F., Govindaswami Ragupathi, David Verbel, et al.. (2002). Thomsen-Friedenreich cluster -KLH conjugate vaccine plus the immunological adjuvant QS21 in prostate cancer. 43. 560. 1 indexed citations
15.
Urist, Marshall, Charles J. Di Como, Elizabeth Charytonowicz, et al.. (2002). Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. American Journal Of Pathology. 161(4). 1199–1206. 212 indexed citations
16.
Morris, Michael J., Timothy Akhurst, Iman Osman, et al.. (2002). Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 59(6). 913–918. 139 indexed citations
17.
Morris, Michael J., Victor E. Reuter, William K. Kelly, et al.. (2002). HER‐2 profiling and targeting in prostate carcinoma. Cancer. 94(4). 980–986. 110 indexed citations
18.
Solit, David B., Fuzhong F. Zheng, Marija Drobnjak, et al.. (2002). 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.. PubMed. 8(5). 986–93. 354 indexed citations
19.
Satagopan, Jaya M., David Verbel, E. S. Venkatraman, Kenneth Offit, & Colin B. Begg. (2002). Two‐Stage Designs for Gene–Disease Association Studies. Biometrics. 58(1). 163–170. 90 indexed citations
20.
Osman, Islam, Howard I. Scher, Marija Drobnjak, et al.. (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.. PubMed. 7(9). 2643–7. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heikki Helin Breakdown of academic impact, for papers by Håvard E. Danielsen Breakdown of academic impact, for papers by Stephen Yip Breakdown of academic impact, for papers by Toby C. Cornish Breakdown of academic impact, for papers by Timo Gaiser Breakdown of academic impact, for papers by Muyan Cai Breakdown of academic impact, for papers by Clare Verrill Breakdown of academic impact, for papers by Giuliana Amaddeo Breakdown of academic impact, for papers by Wentao Yang Breakdown of academic impact, for papers by Bassam Abdulkarim
Rankless by CCL
2026